Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Símbolo de cotizaciónCDXS
Nombre de la empresaCodexis Inc
Fecha de salida a bolsaApr 22, 2010
Director ejecutivoDr. Stephen G. Dilly, Ph.D.
Número de empleados188
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 22
Dirección200 Penobscot Dr
CiudadREDWOOD CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94063
Teléfono16504218100
Sitio Webhttps://www.codexis.com/
Símbolo de cotizaciónCDXS
Fecha de salida a bolsaApr 22, 2010
Director ejecutivoDr. Stephen G. Dilly, Ph.D.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos